{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:18:06Z","timestamp":1787894286561,"version":"build-2784847793"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acquired resistance remains a major challenge in RET fusion-positive non-small cell lung cancer treated with selective RET inhibitors. NTRK fusions represent a rare off-target resistance mechanism in this setting, with limited clinical data to guide management. We report the first case of an acquired TPM3::NTRK1 fusion as a resistance mechanism to selpercatinib in KIF5B::RET-positive lung adenocarcinoma. A male in his late 40s, a non-smoker, underwent surgical resection for NSCLC after incidental detection of a pulmonary lesion. Following disease recurrence, KIF5B::RET was identified as the sole oncogenic driver and the patient achieved durable disease control for 46 months on selpercatinib, with three episodes of oligoprogression managed by stereotactic body radiotherapy. At systemic progression, RNA-inclusive tissue next-generation sequencing (Guardant360 Tissue) identified TPM3::NTRK1 (variant allele fraction 30.9%; RNA 6,109 transcripts per million) and residual KIF5B::RET (variant allele fraction 6.9%), with no secondary RET kinase domain mutations. A concurrent liquid biopsy (cfDNA) assay failed to detect either fusion, with tumor fraction &amp;lt;0.05%, highlighting the limitations of cfDNA-based platforms for fusion detection at low tumor shedding. Combination selpercatinib and larotrectinib was commenced, demonstrating metabolic response on PET-CT at eight weeks with concurrent clinical improvement. This case identifies acquired NTRK1 fusion as a rare, actionable bypass resistance mechanism to selective RET inhibition, distinct from previously reported NTRK3 fusions, and underscores the importance of RNA-based tissue reassessment at progression to guide rational combination targeted therapies.<\/jats:p>","DOI":"10.3389\/fonc.2026.1936583","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:34:18Z","timestamp":1787891658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acquired TPM3::NTRK1 fusion as a novel off-target resistance mechanism to selpercatinib in RET-positive lung adenocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Ritwika","family":"Choudhury","sequence":"first","affiliation":[{"name":"Department of Research (Medical Oncology Unit 5), Rajiv Gandhi Cancer Institute & Research Centre","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Dewan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeena K.","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Venkatraman","sequence":"additional","affiliation":[{"name":"Department of Research (Medical Oncology Unit 5), Rajiv Gandhi Cancer Institute & Research Centre","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute, Division of Oncology, Stanford University School of Medicine","place":["Palo Alto, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullas","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Rajiv Gandhi Cancer Institute & Research Centre","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion\u2013positive non\u2013small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.006","article-title":"Acquired tertiary MET resistance (MET D1228N and a novel LSM8-MET fusion) to selpercatinib and capmatinib in a patient with KIF5B-RET-positive NSCLC with secondary MET amplification as initial resistance to selpercatinib","volume":"16","author":"Zhu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41698-024-00563-4","article-title":"Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer","volume":"8","author":"Subbiah","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.010","article-title":"Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/319743a0","article-title":"A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences","volume":"319","author":"Martin-Zanca","year":"1986","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31110489","article-title":"A novel oncogenic and drug-sensitive KIF5B-NTRK1 fusion in lung adenocarcinoma","volume":"31","author":"Li","year":"2024","journal-title":"Curr Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102733","article-title":"NTRK gene fusion testing and management in lung cancer","volume":"127","author":"Repetto","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1350","article-title":"1293P Mechanisms of resistance to selpercatinib in RET activated NSCLC and MTC from the LIBRETTO-001 trial","volume":"35","author":"Solomon","year":"2023","journal-title":"Ann Oncol"},{"key":"B16","volume-title":"RET-fusion positive lung cancer: Updates on management of fusion-positive NSCLC","author":"Gautschi","year":"2026"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1936583\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:34:32Z","timestamp":1787891672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1936583\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1936583"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1936583","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1936583"}}